287 related articles for article (PubMed ID: 34738088)
1. Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer.
Qiao Y; Choi JE; Tien JC; Simko SA; Rajendiran T; Vo JN; Delekta AD; Wang L; Xiao L; Hodge NB; Desai P; Mendoza S; Juckette K; Xu A; Soni T; Su F; Wang R; Cao X; Yu J; Kryczek I; Wang XM; Wang X; Siddiqui J; Wang Z; Bernard A; Fernandez-Salas E; Navone NM; Ellison SJ; Ding K; Eskelinen EL; Heath EI; Klionsky DJ; Zou W; Chinnaiyan AM
Nat Cancer; 2021 Sep; 2():978-993. PubMed ID: 34738088
[TBL] [Abstract][Full Text] [Related]
2. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
[No Abstract] [Full Text] [Related]
4. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
[TBL] [Abstract][Full Text] [Related]
5. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
De Velasco MA; Kura Y; Fujita K; Uemura H
Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
[TBL] [Abstract][Full Text] [Related]
6. Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy.
Bao Y; Qiao Y; Choi JE; Zhang Y; Mannan R; Cheng C; He T; Zheng Y; Yu J; Gondal M; Cruz G; Grove S; Cao X; Su F; Wang R; Chang Y; Kryczek I; Cieslik M; Green MD; Zou W; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2314416120. PubMed ID: 38011559
[TBL] [Abstract][Full Text] [Related]
7. Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib.
Liu G; Jin Z; Lu X
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230980
[TBL] [Abstract][Full Text] [Related]
8. Boosting anticancer immunotherapy through androgen receptor blockade.
Pala L; De Pas T; Conforti F
Cancer Cell; 2022 May; 40(5):455-457. PubMed ID: 35537411
[TBL] [Abstract][Full Text] [Related]
9. The evolving landscape of immunotherapy in advanced prostate cancer.
Patel VG; Oh WK
Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
[TBL] [Abstract][Full Text] [Related]
10. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer.
Wang L; Wang J; Xiong H; Wu F; Lan T; Zhang Y; Guo X; Wang H; Saleem M; Jiang C; Lu J; Deng Y
EBioMedicine; 2016 May; 7():50-61. PubMed ID: 27322458
[TBL] [Abstract][Full Text] [Related]
11. Understanding the tumor-immune microenvironment in prostate cancer.
Dong L; Myers KV; Pienta KJ
Curr Opin Oncol; 2021 May; 33(3):231-237. PubMed ID: 33606403
[TBL] [Abstract][Full Text] [Related]
12. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
Zorko NA; Ryan CJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
[TBL] [Abstract][Full Text] [Related]
13. Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34.
Janji B; Hasmim M; Parpal S; De Milito A; Berchem G; Noman MZ
Autophagy; 2020 Nov; 16(11):2110-2111. PubMed ID: 32892693
[TBL] [Abstract][Full Text] [Related]
14. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy
Zhou X; Zou L; Liao H; Luo J; Yang T; Wu J; Chen W; Wu K; Cen S; Lv D; Shu F; Yang Y; Li C; Li B; Mao X
Acta Pharm Sin B; 2022 Feb; 12(2):692-707. PubMed ID: 35256940
[TBL] [Abstract][Full Text] [Related]
16. A Novel Salicylanilide Derivative Induces Autophagy Cell Death in Castration-Resistant Prostate Cancer via ER Stress-Activated PERK Signaling Pathway.
Hsieh CL; Huang HS; Chen KC; Saka T; Chiang CY; Chung LWK; Sung SY
Mol Cancer Ther; 2020 Jan; 19(1):101-111. PubMed ID: 31530650
[TBL] [Abstract][Full Text] [Related]
17. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
18. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.
Quinn DI; Shore ND; Egawa S; Gerritsen WR; Fizazi K
Urol Oncol; 2015 May; 33(5):245-60. PubMed ID: 25575714
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
